Afrigen Biologics, a research, development and manufacturing company specializing in the development of mRNA vaccines and therapeutics, announced a significant collaboration with RespIP BV, an affiliate of ForgeBio BV, an antigen design company based in the Netherlands, to evaluate Forge Bio’s prefusion-stabilized F antigens for use in a prophylactic mRNA vaccine against respiratory syncytial virus (RSV) on Afrigen’s end-to-end mRNA platform.
